Dabigatran in patients with atrial fibrillation after COVID-19 hospitalization: an update of the ANIBAL protocol

COVID-19 increases the risk of atrial fibrillation (AF) and thrombotic complications, particularly in severe cases, leading to higher mortality rates. Anticoagulation is the cornerstone to reduce thromboembolic risk in patients with AF. Considering the risk of hepatotoxicity in patients with severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Cerezo-Manchado, Juan José, Meca Birlanga, Olga, García de Guadiana Romualdo, Luis, Gil-Ortega, Ignacio, Martínez Francés, Antonio, Iturbe-Hernandez, Teodoro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798364/
https://www.ncbi.nlm.nih.gov/pubmed/35145555
http://dx.doi.org/10.7573/dic.2021-9-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798364/
https://www.ncbi.nlm.nih.gov/pubmed/35145555
http://dx.doi.org/10.7573/dic.2021-9-4

Ejemplares similares